Mission Wealth Management LP Sells 35,315 Shares of Inogen, Inc. (NASDAQ:INGN)

Mission Wealth Management LP trimmed its holdings in Inogen, Inc. (NASDAQ:INGN) by 46.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,320 shares of the medical technology company’s stock after selling 35,315 shares during the quarter. Mission Wealth Management LP’s holdings in Inogen were worth $333,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Kingswood Wealth Advisors LLC acquired a new position in Inogen in the 1st quarter valued at approximately $123,000. Quadrature Capital Ltd lifted its position in Inogen by 106.4% in the fourth quarter. Quadrature Capital Ltd now owns 31,071 shares of the medical technology company’s stock worth $171,000 after purchasing an additional 16,017 shares during the period. PNC Financial Services Group Inc. increased its holdings in Inogen by 2,918.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock valued at $43,000 after buying an additional 7,646 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Inogen by 84.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the medical technology company’s stock valued at $29,000 after buying an additional 2,419 shares in the last quarter. Finally, Olympiad Research LP bought a new position in shares of Inogen during the 4th quarter worth about $97,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Inogen Trading Up 2.1 %

Shares of Inogen stock traded up $0.17 during mid-day trading on Friday, reaching $8.25. 88,175 shares of the stock were exchanged, compared to its average volume of 134,001. Inogen, Inc. has a fifty-two week low of $4.13 and a fifty-two week high of $10.81. The firm has a 50-day simple moving average of $8.09 and a 200 day simple moving average of $7.34.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.14. The company had revenue of $78.03 million during the quarter, compared to analyst estimates of $73.67 million. Inogen had a negative net margin of 30.07% and a negative return on equity of 42.87%. The company’s revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.63) earnings per share. Research analysts expect that Inogen, Inc. will post -2.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INGN has been the topic of a number of analyst reports. Stifel Nicolaus upped their target price on shares of Inogen from $6.00 to $7.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Wednesday, May 8th. Finally, StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a research report on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.00.

Insider Activity at Inogen

In other Inogen news, EVP Jason Somer sold 10,000 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $8.56, for a total value of $85,600.00. Following the transaction, the executive vice president now owns 4,452 shares of the company’s stock, valued at $38,109.12. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.99% of the company’s stock.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.